01-05-2023, 11:37 AM
The companies Pfizer and BioNTech ("Pfizer"/"Biontech") have offered European Union countries to pay half the cost of their COVID-19 vaccine that has been ordered but is no longer needed or will not be needed in the next few years .
The news was reported today by the Financial Times, with Reuters citing that the article described how, in a possible revision of the treaty, the EU would be able to demand the latest vaccines tailored to variants of the coronavirus that may appear in the future.
The agency said in January that the two drug companies and the EU were in talks to cut nearly 500 million doses ordered for 2023 in exchange for a higher price.
According to the Financial Times, the condition for the unused doses is part of a larger contract under which BioNTech/Pfizer offers about 70 million doses against COVID-19 annually until 2026. The publication notes that such a number would push out rivals Moderna, Novavax and Sanofi from the market - and for them there were already smaller orders at the height of the pandemic - and almost complete dominance of just one product.
Poland and other Eastern European countries had refused to sign an annex to the treaty because they did not want to pay for unused doses, the Financial Times also claimed.
https://www.dnevnik.bg/sviat/2023/04/30/...ome_layer2
The news was reported today by the Financial Times, with Reuters citing that the article described how, in a possible revision of the treaty, the EU would be able to demand the latest vaccines tailored to variants of the coronavirus that may appear in the future.
The agency said in January that the two drug companies and the EU were in talks to cut nearly 500 million doses ordered for 2023 in exchange for a higher price.
According to the Financial Times, the condition for the unused doses is part of a larger contract under which BioNTech/Pfizer offers about 70 million doses against COVID-19 annually until 2026. The publication notes that such a number would push out rivals Moderna, Novavax and Sanofi from the market - and for them there were already smaller orders at the height of the pandemic - and almost complete dominance of just one product.
Poland and other Eastern European countries had refused to sign an annex to the treaty because they did not want to pay for unused doses, the Financial Times also claimed.
https://www.dnevnik.bg/sviat/2023/04/30/...ome_layer2